In non-small-cell lung cancer, EGCG, enhanced the levels of mir-485-5p, suppressing the levels of two oncogenic targets, CD44 and the nuclear receptor RXRα, both effects contributing to the decrease in CSC-like properties [139,140]. This evidence concerns the gene CD44 and non-small cell lung carcinoma.